期刊
MOLECULAR PHARMACEUTICS
卷 5, 期 1, 页码 49-59出版社
AMER CHEMICAL SOC
DOI: 10.1021/mp700110z
关键词
nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; liver disease; liver cirrhosis; hepatic fibrosis; nuclear receptors; fibrates; thiazolidinediones; adiponectin; fatty acids; bile acids
Nonalcoholic fatty liver disease (NAFLD) is a consequence of insulin resistance encompassing a spectrum that extends from simple hepatic steatosis through to nonalcoholic steatohepatitis (NASH), a condition that may progress to cirrhosis with its associated complications. A subset of nuclear receptors act as intracellular sensors for cholesterol metabolites, free fatty acids, and a range of other lipophilic molecules with pivotal roles in energy homeostasis and inflammation. These receptors represent attractive drug targets for the management of NAFLD and NASH as well as related conditions such as type 2 diabetes and the broader metabolic syndrome. To date, human studies have concentrated on peroxisome proliferator-activated receptor (PPAR) agonists, particularly those directed at PPAR gamma. However, these drugs have significant limitations, so alternate approaches to nuclear receptor targeting are being explored.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据